 LEIDEN, Netherlands CAMBRIDGE, Mass., March 24, 2021 GLOBE NEWSWIRE -- ProQR Therapeutics N.V. Nasdaq: PRQR the Company, a company dedicated to changing lives through the creation of transformative RNA therapies for inherited retinal diseases IRDs, today announced results from a planned analysis of its Phase 12 Stellar trial of QR-421a in adults with Usher syndrome and non-syndromic retinitis pigmentosa nsRP due to USH2A exon 13 mutations. In the trial, QR-421a demonstrated benefit on multiple measures of vision that moved in concordance, including visual acuity, visual fields, and optical coherence tomography OCT retinal imaging, after a single dose. QR-421a was observed to be well tolerated with no serious adverse events reported. Based on these findings, the Company plans to advance QR-421a to two parallel pivotal Phase 23 trials by year end 2021 one in early-moderate patients, one in advanced patients. 